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Purpose or Objective: For the locally advanced prostate 
cancers (LAPC) dose escalated external beam Radiotherapy 
(dEBRT) with androgen deprivation therapy (ADT) for 2-3 
years is the current standard of care. The role of radical 
prostatectomy (RP) for high-risk prostate cancer is still 
debated. Better outcomes with RP as compared to dEBRT 
especially <69 years of age has been reported. However there 
is no data available from India to compare dEBRT and RP. We 
did a retrospective study to compare dEBRT or RP in patients 
with LAPC.  
 
Material and Methods: Medical records of 77 high risk LAPC 
treated between 2008-2013 were analysed. All biopsy proven 
adenocarcinoma of prostate with high risk category 
(PSA>20ng/ml or Gleason score (GS) >7 or T2c-T4) were 
included. Patients either underwent dEBRT with image 
guided RT (IGRT) (group 1) or RP (group 2) along with ADT for 
2-3 years. Group 1 and 2 had 37 and 40 patients respectively. 
The primary end points of the study were biochemical relapse 
free survival (bRFS), bladder and rectal toxicity, urinary 
incontinence (UI) and secondary end point was cancer 
specific survival (CSS). 
 
Results: Median age and median pre-treatment PSA in 2 
groups were comparable (66 and 65years) and (22 and 23 
ng/ml) respectively. Radiologically T3/T4 lesions were 
present in 65% and 68% and nodal metastasis was seen in 22% 
and 30% respectively. Median GS was 8 and 7. Positive 
surgical margins was seen in 70% in group 2. dEBRT dose was 
76Gy with conventional fractionation using IGRT using 
fiducial marker matching . With a median follow up of 3 
years, 5-year bRFS was 78% and 72%. (p=0.12) .Median bRFS 
was not reached in group 1 and in group 2, it was 79 months. 
Post treatment UI was seen in 0 and 6(15%)(p=0.03). 
Radiation Therapy Oncology Group (RTOG) grade III-IV 
bladder toxicity (hematuria and bladder neck contracture 
requiring incision) was seen in 2(6%) and 7(18%) respectively 
and rectal toxicity in 2(6%) and peroperative rectal injury 
occurred in 2(5%) in group 2. Five year CSS was 65% and 87% 
respectively (p=0.086). Median CSS was not reached in any 
group. Six (16%) and 7(18%) patients were lost to follow up. 
Distant metastasis was seen in 8(22%) and 1(3%) (p=0.14). 
 
Conclusion: UI is the complication associated with RP. Dose 
escalated IGRT for LAPC is no different from RP in terms of 
bRFS however there was a trend towards better CSS and 
distant DFS. Further long term follow up is needed to assess 
the effect on distant disease free survival and CSS.  
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Purpose or Objective: Radical cystectomy (RC) and pelvic 
lymph-node dissection (PLND) are standard procedures in the 
management of non-metastatic muscle invasive bladder 
cancer (MIBC). Loco-regional recurrence (LRR) is a common 
early event associated with a poor prognosis. The aim of this 
study is to evaluate adjuvant radiotherapy (RT) for 
pathological high-risk MIBC.  
 
Material and Methods: We retrospectively reviewed data 
from patients treated by RC from 3 institutions. Inclusion 
criteria were MIBC, histologically proven urothelial carcinoma 
treated by RC and adjuvant RT. Patients with conservative 
surgery were excluded. LRR free-survival, overall survival 
(OS) and metastasis-free survival (MFS) were evaluated. 
Acute toxicities were recorded according to CTCAE V4.0 
scale. 
 
Results: Between January 2000 and December 2013, 57 
patients with a median age of 66 years (45-84) were 
included. Post-operative pathological staging was pT2, pT3 
and pT4 in 16%, 44%, and 39%, respectively. PLND revealed 
28% of pN0, 26% of pN1 and 42% of pN2. For 2 patients, no 
PLND was performed. Median number of lymph-nodes 
retrieved was 10 (2-33). Forty-eight patients (84%) received 
platin-based chemotherapy, 7 in neo-adjuvant and 41 in 
adjuvant setting. For RT, clinical target volume 1 (CTV 1) 
encompasses pelvic lymph nodes for all patients. CTV 1 also 
included cystectomy bed for 37 patients (65%). Median dose 
for CTV 1 was 45 Gy (4-50). Dose complement of 16 Gy (5-22) 
corresponding to CTV 2 was achieved in 53 of cases, 
depending on pathological features. Intensity Modulated RT 
was performed in one third of patients. With a median 
follow-up of 40.4 months, LRR occurred in 8 patients (14%) 
that appeared concomitantly with metastasis in two-third of 
cases. Three-year loco-regional free survival, MFS and OS 
were 45% (IC 95% 0.30-0.60), 39% (IC 95%, 0.25-0.52) and 49% 
(IC 95%, 0.33-0.63), respectively. Acute grade ≥3 toxicities 
were observed in 5 patients (9%). One patient died with 
intestinal fistula in septic context. No survival or toxicity 
predictive factor was identified. 
 
Conclusion: Adjuvant radiotherapy for pathological high-risk 
MIBC is safe and may have oncological benefits. Thus, new 
prospective trials evaluating this approach with modern RT 
techniques should be undertaken. 
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Purpose or Objective: To analyze patients treated for 
recurrent urothelial cancer with radiation therapy with or 
without concomitant chemotherapy after surgical 
intervention that was treated from 2000 to 2012 at our 
centre. 
 
Material and Methods: Our inclusion strategy was to first 
identify patients treated for the relevant ICD-10 codes. A 
number of 270 patients matched the ICD-10 criteria (see 
CONSORT diagram). In a second step, patients that were 
treated at other sites than the pelvis, treated for distant 
metastasis, patients suffering from renal cell cancer and 
cancer of the renal pelvis were excluded. In a third step 
patients treated with radiation doses that are typical for 
palliation (<45Gy) were excluded from the analysis. After 
this, a number of 57 patients remained at the database for 
further analyses. All patients were treated for recurrent 
urothelial cancer of the bladder, of the ureter or of the 
urethra. All patients were treated using 3D conformal 
radiation therapy. Mean prescribed dose was 54.22Gy (range 
45-72Gy). Mean time from first diagnosis to 
radio(chemo)therapy was 22.9 months (range one week to 
276 months). In 24 cases (42.1 %) a concomitant 
chemoradiotherapy was applied. 
 
Results: Mean survival from the beginning of radiation 
treatment was 39.2 months (CI 95 % 24.7 – 53.69 months; 
median survival 14 months CI 95% 6.8 -21.1). Tumor stage at 
the time of surgical intervention did not show an impact on 
overall survival (p=0.96). Patients were divided into three 
subgroups, depending on the surgical intervention prior to 
radiation therapy: most patients were treated by TUR(n=38) 
before the indication to radiation therapy was made, 13 
patients had a TUR followed by cystectomy in their further 
history and in 6 patients early cystectomy was the first type 
